A Randomized, Double-Blind, Phase III Study Comparing FTD/TPI Therapy Versus Placebo in Patients Who Are Positive for Blood Circulating Tumor DNA After Curative Resection of Colorectal Cancer
Latest Information Update: 01 Aug 2023
Price :
$35 *
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms ALTAIR
- 28 Jul 2023 Status changed from recruiting to active, no longer recruiting, according to Natera media release.
- 28 Jul 2023 According to a Natera media release, company announced completion of enrollment.
- 28 Jul 2023 According to a Natera media release, company expects to share primary results from ALTAIR in mid-2024.